MedPath

Clinical Study on Grade 1 Essential Hypertension and Comparative Evaluation of Habbul Buzoor With Standard Control Drug Telmisartan in its Management.

Not Applicable
Not yet recruiting
Conditions
Health Condition 1: I10- Essential (primary) hypertension
Registration Number
CTRI/2021/10/037024
Lead Sponsor
Deptt of Moalejat Ajmal khan tibbiya college and hospital faculty of medicine AM
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Not Yet Recruiting
Sex
Not specified
Target Recruitment
0
Inclusion Criteria

Clinically diagnosed patients of Grade 1 (According to WHO/ISH,SBP-140-159 mm of Hg and DBP-90-99 mm of Hg)2 essential hypertension on three consecutive visits under optimal conditions.

Patients of either gender.

Patients in the age group of 18 to 60 years.

No evidence of target organ damage should be present.

Patients not taking any anti-hypertensive drugs prior to state of treatment.

Clinically stable patients.

Those who give written consent.

Exclusion Criteria

Patients of severe or malignant hypertension.

Patients of Secondary hypertension.

Patients below 18 years of age.

Pregnant women and lactating mothers.

Patients with unstable systemic disorders like liver,kidney or heart diseases etc.

Patients with Clinical or laboratory evidence of target organ damage.

Terminally ill patients like infectious diseases ,AIDS,Tuberculosis etc.

Smokers and alcoholics.Patients who do not sign informed consent form.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Efficacy will be assessed clinically by recording reading of systolic and diastolic blood pressure and relief in symptoms(if present) <br/ ><br> <br/ ><br>Timepoint: 2 months with every 2 week followup <br/ ><br>
Secondary Outcome Measures
NameTimeMethod
relief in symptoms(if present) <br/ ><br>Timepoint: 2 months with every 2 week followup
© Copyright 2025. All Rights Reserved by MedPath